URGN Class Action News: UroGen Pharma Ltd. Investors with Large Losses Should Contact Robbins LLP Before July 28 for Information About Leading the Class ActionSAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (
NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025. UroGen engages in the development and commercialization of solutions for specialty cancers. The Company’s lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer.
UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Against UroGen Pharma Ltd. And Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options
Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the FirmNEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) for violations of the federal securities laws on behalf of investors who purchased or acquired UroGen securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”).
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Organon (OGN), UroGen (URGN), Red Cat (RCAT), or Fortrea (FTRE) To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the FirmNEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc (OTC:RBGLY), UroGen Pharma Ltd. (
NASDAQ:URGN), Red Cat Holdings, Inc. (
NASDAQ: RCAT) and Fortrea Holdings Inc. (
NASDAQ:FTRE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerPRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has completed patient enrollment in its Phase 3 UTOPIA clinical trial of UGN-103 (mitomycin) for intravesical solution, a next-generation formulation in development for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGNNEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (
NASDAQ: URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGNNEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (
NASDAQ: URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc (OTC:RBGLY), UroGen Pharma Ltd. (
NASDAQ:URGN), Red Cat Holdings, Inc. (
NASDAQ: RCAT) and Fortrea Holdings Inc. (
NASDAQ:FTRE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for InformationSAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (
NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025. UroGen engages in the development and commercialization of solutions for specialty cancers. The Company’s lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGNNEW YORK, NY / ACCESS Newswire / June 30, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. ("UroGen" or the "Company") (
NASDAQ:URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNNEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (“UroGen” or the “Company”) (
NASDAQ: URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in UroGen Pharma Ltd. of Class Action Lawsuit And Upcoming Deadlines - URGNNEW YORK CITY, NY / ACCESS Newswire / June 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. ("UroGen" or the "Company") (
NASDAQ:URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNNEW YORK CITY, NY / ACCESS Newswire / June 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (
NASDAQ:URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNNEW YORK CITY, NY / ACCESS Newswire / June 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (
NASDAQ:URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the FirmNEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc (OTC:RBGLY), UroGen Pharma Ltd. (
NASDAQ:URGN), Red Cat Holdings, Inc. (
NASDAQ: RCAT) and Fortrea Holdings Inc. (
NASDAQ:FTRE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNNEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (“UroGen” or the “Company”) (
NASDAQ: URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the FirmNEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) for violations of the federal securities laws on behalf of investors who purchased or acquired UroGen securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNNEW YORK CITY, NY / ACCESS Newswire / June 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (
NASDAQ:URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNNEW YORK CITY, NY / ACCESS Newswire / June 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (
NASDAQ:URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGNNEW YORK CITY, NY / ACCESS Newswire / June 20, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. ("UroGen" or the "Company") (
NASDAQ:URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNNEW YORK CITY, NY / ACCESS Newswire / June 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (
NASDAQ:URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNNEW YORK, NY / ACCESS Newswire / June 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (
NASDAQ:URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNNEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (“UroGen” or the “Company”) (
NASDAQ: URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the FirmNEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc (OTC:RBGLY), UroGen Pharma Ltd. (
NASDAQ:URGN), Red Cat Holdings, Inc. (
NASDAQ: RCAT) and Fortrea Holdings Inc. (
NASDAQ:FTRE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
